巴西媒體：研究者稱普克魯胺本可成為巴西13.7萬新冠患者的"救命藥"
據巴西媒體報道，巴西Samel醫院和主要研究者2022年1月24日在瑪瑙斯舉行了約3小時新聞發佈會展示了普克魯胺治療重症新冠的亮眼數據。研究人員表示，普克魯胺本可以挽救2021年4月至7月之間巴西13.7萬名因新冠去世的患者。以下為原文報道翻譯摘錄：
新聞發佈會視頻：https://youtu.be/ZA0opm2XkjA
當地時間2022年1月24日，巴西Samel醫院和Flávio Cadegiani醫生在瑪瑙斯舉行了新聞發佈會，會上展示了普克魯胺在巴西治療重症新冠患者研究者臨牀試驗的最終亮眼數據。Samel醫院和Flávio Cadegiani醫生是此項試驗的臨牀中心醫院和主要研究者之一。
普克魯胺自2021年2月起在巴西進行上述該項針對重症新冠患者的臨牀試驗，結果顯示普克魯胺效果優異。數據顯示：巴西南部和北部的重症新冠患者使用普克魯胺後，14天內死亡率降低了80%，28天死亡率降低78%，住院時間縮短58%，第14天康復速度快121%。巴西南部和北部進行的臨牀試驗結果體現了一致的有效性。
普克魯胺治療重症新冠患者這項試驗的亮眼結果也在國際科學雜誌《Cureus》上發表。這項研究在該雜誌評估的所有細項中都獲得了最高評分，也成為《Cureus》歷史上評分最高的臨牀研究。
該研究發表在科學雜誌《Cureus》上: https://www.cureus.com/articles/80171-final-results-of-a-randomized-placebo-controlled-two-arm-parallel-clinical-trial-of -proxalutamide-for-hospitalized-covid-19-patients-a-multiregional-joint-analysis-of-the-proxa-rescue-androcov-trial
關於該研究
該研究於2021年2月在巴西亞馬遜州開展，由美國、巴西研究人員和Samel醫院合作開展。Samel醫院因其在醫院護理方面的各種卓越認證獲此合作機會。
參考資料
According to a researcher, more than 137 thousand victims of Covid19 could have been saved between April and June in Brazil
https://www.amazonasreporter.com.br/segundo-pesquisador-mais-de-137-mil-pacientes-vitimas-da-covid19-poderiam-ter-sidos-salvas-entre-os-meses-abril-e-junho-no-brasil/
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
